Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab in Chronic Obstructive Pulmonary Disease (ARNASA)
NCT05595642Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 36
01
Overview
A Phase 3 trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Started Dec 2022; status: completed.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05595642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595642.